Publications by authors named "A J Bredenoord"
Background And Aims: Budesonide orodispersible tablets (BOT) have been shown to be safe and effective in phase 3 double-blind trials of induction and 48-week maintenance therapy of eosinophilic esophagitis (EoE). We now analyzed the long-term efficacy and safety of BOT in a 96-week open-label extension (OLE) study.
Methods: All EoE patients in the 48-week double-blind maintenance study were eligible to receive BOT treatment for up to 96 weeks.
Background: EsoCap is a thin mucoadhesive film designed to target the oesophageal mucosa. The device loaded with mometasone furoate (ESO-101) is under investigation for the treatment of eosinophilic oesophagitis (EoE).
Aims: To evaluate the efficacy, safety and tolerability of ESO-101 in patients with active EoE.
Background And Aim: Our aim was to evaluate outcomes of maintenance treatments for EoE among observational studies (OSs) and randomized controlled trials (RCTs).
Materials And Methods: Studies reporting histological success of maintenance therapy ≥ 48 weeks were included. Primary outcome was histological success rate (defined as <15/<6 eos/HPF).
Article Synopsis
- GERD is a common digestive disorder that is often treated with proton pump inhibitors (PPIs), but some patients look for natural alternatives like Benesco™, which contains quercetin.
- This study assessed the effects of Benesco™ on esophageal sensitivity, barrier function, and reflux symptoms in patients diagnosed with GERD.
- The results showed no significant improvements in acid perception, mucosal barrier function, or reflux symptoms after treatment with Benesco™, indicating it may not be effective for GERD management.